Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.
about
Trop-2 is a determinant of breast cancer survivalHigh expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo.Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).Trop2 is overexpressed in gastric cancer and predicts poor prognosis.The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.Trop2: from development to disease.Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.Sacituzumab govitecan: an antibody-drug conjugate.TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation.Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.High Eg5 expression predicts poor prognosis in breast cancer.LAMP1 expression is associated with poor prognosis in breast cancer.Significant associations between driver gene mutations and DNA methylation alterations across many cancer types.Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type.Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.New agents for the management of resistant metastatic breast cancer.The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target.
P2860
Q27333611-8B8ED3E6-5D90-4E04-9AFF-972A1F3EDD52Q33867326-A185D66A-75D3-4CEF-95FD-9839093003E7Q34975326-4EF2EB06-9AFE-45C5-A297-9489AE2301EDQ36356001-19BAAD34-57AF-4D2C-9442-FAECC4A2CABFQ36905863-0C2441BA-35DB-430B-8709-ED660368302FQ37269458-2CBC8D59-C452-4962-A0E3-751B4C780909Q38293559-CC7C59D8-D955-480A-B784-1FE1AF819CC9Q38375607-A33054E0-AC9A-4386-85D2-241D4091D565Q38683957-3B1F38CF-06AB-4AF0-ABBC-F2C907AAB2A7Q38748274-AC6E5500-8BB0-4D38-9228-48521B585B7CQ38774676-900C894D-E816-4DB1-956D-076528EEB594Q42365330-3D46B638-4730-4EF6-9310-AD96503F4475Q42908311-A0A800A5-AB30-4235-8AAC-084BB96A20D4Q47100621-02B9E940-F5A1-419E-B680-630705F3C909Q47147021-893313C0-1336-4C8E-BD26-908067B9968CQ47694775-E57C9A7E-8F9D-4A7E-B5E4-E459EB8CC75DQ47851750-493B52D4-D037-4455-B844-4CBC0B063506Q48240854-6DA7ABD2-5FCF-4FCE-8408-E0D461ECE80BQ55508847-61A7371A-EEC2-4B55-B29A-8CBBC84723F4
P2860
Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Significantly upregulated TACS ...... invasive ductal breast cancer.
@en
Significantly upregulated TACS ...... invasive ductal breast cancer.
@nl
type
label
Significantly upregulated TACS ...... invasive ductal breast cancer.
@en
Significantly upregulated TACS ...... invasive ductal breast cancer.
@nl
prefLabel
Significantly upregulated TACS ...... invasive ductal breast cancer.
@en
Significantly upregulated TACS ...... invasive ductal breast cancer.
@nl
P2093
P1476
Significantly upregulated TACS ...... invasive ductal breast cancer.
@en
P2093
Chang-Jun Wang
Hui-Lin Zhang
Jian-Fei Huang
Jin-Rong Qiu
Xiao-Jun Tang
Zhen-Qing Feng
Zhong-Can Wang
P356
10.1016/J.YEXMP.2012.08.004
P577
2012-09-29T00:00:00Z